Cellosaurus logo
expasy logo

Cellosaurus BCPAP-R (CVCL_A8S1)

[Text version]
Cell line name BCPAP-R
Accession CVCL_A8S1
Resource Identification Initiative To cite this cell line use: BCPAP-R (RRID:CVCL_A8S1)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Asp259Tyr (c.775G>T); ClinVar=VCV000634680; Zygosity=Homozygous (from parent cell line).
Disease Poorly differentiated thyroid gland carcinoma (NCIt: C6040)
Thyroid carcinoma (ORDO: Orphanet_100088)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0153 (B-CPAP)
Sex of cell Female
Age at sampling 76Y
Category Cancer cell line
Publications

PubMed=32666385; DOI=10.1007/s12020-020-02417-y
Run L., Wang L.-P., Nong X.-T., Li N., Huang X., Xiao Y.
Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
Endocrine 71:418-426(2021)

Cross-references
Cell line databases/resources cancercelllines; CVCL_A8S1
Encyclopedic resources Wikidata; Q102113611
Entry history
Entry creation29-Oct-2020
Last entry update05-Oct-2023
Version number8